ISSN 1866-8836
Клеточная терапия и трансплантация

Editorial article

Professor Boris V.Afanasyev, Editor-in-Chief, Cellular Th erapy and Transplantation
Professor Axel R. Zander (Germany), Co-Editor-in Chief, CTT Journal
Professor Gerard Wagemaker (Netherlands), Co-Editor-in Chief, CTT Journal
doi 10.18620/ctt-1866-8836-2017-6-4-10-12

Download PDF version

Cellular Therapy and Transplantation (CTT)
Volume 6, Number 4


Dear CTT authors and reviewers,
First of all, we would like to express our deep gratitude for your work on preparing and submitting your papers to our Journal as well as for reviewing the submissions, thus providing an important support to the CTT Journal over last years. Moreover, the Editors express a hope that this co-operation will be more advanced with time, expanding the membership of specialists publishing their data in CTT, both from Russia and abroad.
Publication in this journal is a great opportunity for the Russian as well as international specialists to publish Scopuscited research in English. The Journal provides fast and adequate peer reviewing, language editing and summaries in Russian to broaden the readers’ audience.
The Journal focuses on both preclinical and clinical aspects of cellular therapy and transplantation. In spite of numerous targeted drugs implemented over last years, e.g., PD-1 modulators, novel kinase inhibitors, monoclonal antibodies, gene therapy approaches, which have now changed the therapeutic landscape in hematology/oncology, the role of allogeneic hematopoietic stem cell transplantation (HSCT) is not diminishing, but rapidly growing, because more patients become eligible due to improvement of the disease status after targeted therapy, and more patients have long-term disease control due to disease-specifi c prophylaxis or pre-emptive strategies aft er transplantation. Thus the Journal welcomes articles addressing various aspects of improving the outcome after HSCT, including pre- and post-transplant therapy, conditionin regimens, and graft -versus-host-disease prophylaxis.
Another focus of the journal is on preclinical studies, because HSCT is now becoming the backbone of gene therapy, drug delivery strategies and immunotherapy. We welcome the researchers with their results on in vitro models that evaluate the efficacy of gene editing, immunological aspects of cancer therapy and novel approaches to antineoplastic drug delivery.
Hence, we wish much success in your studies, being in more close cooperation with Russian colleagues and the CTT Journal, which is ready to publish novel and original results in clinical and experimental cellular therapy.

Back to the list